Biomarkers play a vital role in precision medicine, from the development of novel targeted therapies and diagnostics to clinical biomarker applications. Biognosys’ Tissue Biomarker Discovery service offers a proteome coverage of 13,800 proteins to identify the most promising, actionable biomarkers to support clinical decision-making.
Our TrueDiscovery® platform for tissue biomarker discovery utilizes Hyper Reaction Monitoring (HRM™). This proprietary Biognosys technology enables specific and unbiased discovery through the quantification of complete proteomes and phospho-proteomes. Further, the platform leverages our flagship software, Spectronaut®, for Artificial Intelligence and Machine Learning (AI/ML) enhanced proteomics data analysis.
The service offers a choice of depth for the identification of differentially regulated proteins in a hypothesis-free manner. We also provide highly multiplexed targeted proteomics with absolute quantification for customized panels of proteins.
Tissue Biomarker Discovery can be applied on a large scale, analyzing thousands of proteins across thousands of samples in a high-throughput mode.
“Biognosys’ high depth and high throughput proteomics technology allows us to take an unbiased deep dive into the molecular mechanisms underlying cancer. Furthermore, the data quality will facilitate our Pan-Cancer therapeutic target and biomarker discovery work-flows, giving us confidence that novel findings closely represent the underlying patient biology.”
Jonathan Woodsmith, Ph.D.,
VP Advanced Analytics and AI, Indivumed
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteom [...]
Advances in mass spectrometry proteomics now make it possible to achieve unprecedented depth and coverage faster than ever before. In this case study we demonstrate the advantages [...]
Roland Bruderer, Head of R&D LC-MS and Workflows, will guide you through discovering the fascinating world of tissue proteomics and explain how deep we can now explore the tiss [...]
Our new White Paper explains why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research.
Despite significant advancements in melanoma treatment using immune checkpoint inhibitors, many patients do not show a clinical benefit. To better understand the mechanisms driving [...]
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel formats.
a) Normalized relative protein intensities for all detected proteins or absolute quantities if stable isotope standards were used
b) Protein annotation (based on Uniprot Knowledgebase)
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g. PCA)
d) Hierarchical clustering analysis
e) Functional analysis (e.g. GO/Pathway analysis)
f) Custom analysis upon request
Tissue Biomarker Discovery can be applied to all types of solid biological matrices, such as frozen tissue, FFPE slides, or cell cultures from virtually any species. Only a limited amount of material is required.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.